Robust and discordant evidence: Methodological lessons from clinical research

Philosophy of Science

Volumn 82, Issue 1, 2014, Pages 55-75

  Hey, Spencer Phillips ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924785686     PISSN: 00318248     EISSN: 1539767X     Source Type: Journal    
DOI: 10.1086/678978     Document Type: Article

References (40)

1. Burman, William J., et al. 2006. “Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis.” American Journal of Respiratory and Critical Care Medicine 174:331-38.
2. Chapin, Charles V. 1910. The Sources and Modes of Infection. New York: Wiley.
3. Conde, Marcus B., et al. 2009. “Moxifloxacin versus Ethambutol in the Initial Treatment of Tuberculosis: A Double-Blind, Randomised, Controlled Phase II Trial.” Lancet 373:1183-89.
4. Culp, Sylvia. 1994. “Defending Robustness: The Bacterial Mesosome as a Test Case.” In PSA 1994: Proceedings of the 1994 Biennial Meeting of the Philosophy of Science Association, ed. David Hull, Micky Forbes, and Richard M. Burian, 46-57. East Lansing, MI: Philosophy of Science Association.
5. Dorman, Susan E., et al. 2009. “Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis.” American Journal of Respiratory and Critical Care Medicine 180:273-80.
6. Franklin, Allan. 2002. Selectivity and Discord: Two Problems of Experiment. Pittsburgh: University of Pittsburgh Press.
7. Freedman, Benjamin. 1987. “Equipoise and the Ethics of Clinical Research.” New England Journal of Medicine 317:141-45.
8. Gillespie, Stephen, and O. Billington. 1999. “Activity of Moxifloxacin against Mycobacteria.” Journal of Antimicrobial Chemotherapy 44:393-95.
9. Gillespie, Stephen H., Roly D. Gosling, Leonard Uiso, Noel E. Sam, Esther G. Kanduma, and Timothy D. McHugh. 2005. “Early Bactericidal Activity of a Moxifloxacin and Isoniazid Combination in Smear-Positive Pulmonary Tuberculosis.” Journal of Antimicrobial Chemotherapy 56:1169-71.
10. Gosling, Roly D., Leonard O. Uiso, Noel E. Sam, Emily Bongard, Esther G. Kanduma, Mramba Nyindo, Richard W. Morris, and Stephen H. Gillespie. 2003. “The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis.” American Journal of Respiratory and Critical Care Medicine 168:1342-45.
11. Hall, Caroline B. 2007. “The Spread of Influenza and Other Respiratory Viruses: Complexities and Conjectures.” Clinical Infectious Diseases 45:353-59.
12. Hay, Michael, David W. Thomas, John L. Craighead, Celia Economides, and Jesse Rosenthal. 2014. “Clinical Development Success Rates for Investigational Drugs.” Nature Biotechnology 32:40-51.
13. Hey, Spencer P., Charles M. Heilig, and Charles Weijer. 2013. “Accumulating Evidence and Research Organization (AERO) Model: A New Tool for Representing, Analyzing, and Planning a Translational Research Program.” Trials 14:159.
14. Ji, Baohong, Nacer Lounis, Caroline Maslo, Chantal Truffot-Pernot, Pascale Bonnafous, and Jacques Grosset. 1998. “In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium Tuberculosis.” Antimicrobial Agents and Chemotherapy 42:2066-69.
15. Johnson, J., et al. 2006. “Early and Extended Early Bactericidal Activity of Levofloxacin, Gatifloxacin and Moxifloxacin in Pulmonary Tuberculosis.” International Journal of Tuberculosis and Lung Disease 10:605-12.
16. Levins, Richard. 1966. “The Strategy of Model Building in Population Biology.” American Scientist 54:421-31.
17. Levins, Richard. 1993. “A Response to Orzack and Sober: Formal Analysis and the Fluidity of Science.” Quarterly Review of Biology 68:547-55.
18. Lounis, Nacer, Abdelhalim Bentoucha, Chantal Truffot-Pernot, Baohong Ji, Richard J. O’Brien, Andrew Vernon, Giorgio Roscigno, and Jacques Grosset. 2001. “Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium Tuberculosis in Mice.” Antimicrobial Agents and Chemotherapy 45:3482-86.
19. Mac Kenzie, William R., et al. 2011. “Geographic Differences in Time to Culture Conversion in Liquid Media: Tuberculosis Trials Consortium Study 28; Culture Conversion Is Delayed in Africa.” PLoS One 6:e18358.
20. Mateo, Joaquin, Michael Ong, David S. P. Tan, Michael A. Gonzalez, and Johann S. de Bono. 2013. “Appraising Iniparib, the Parp Inhibitor That Never Was—What Must We Learn?” Nature Reviews Clinical Oncology 10:688-96.
21. Miyazaki, Eishi, Miki Miyazaki, Jong Min Chen, Richard E. Chaisson, and William R. Bishai. 1999. “Moxifloxacin (bay12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis.” Antimicrobrial Agents and Chemotherapy 43:85-89.
22. Nuermberger, Eric L., Tetsuyuki Yoshimatsu, Sandeep Tyagi, Richard J. O’Brien, Andrew N. Vernon, Richard E. Chaisson, William R. Bishai, and Jacques H. Grosset. 2004. “Moxifloxacin-Containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis.” American Journal of Respiratory and Critical Care Medicine 169:421-26.
23. Orzack, Steven H., and Elliott Sober. 1993. “A Critical Assessment of Levins’s ‘The Strategy of Model Building in Population Biology’ (1966).” Quarterly Review of Biology 68:533-46.
24. Pletz, Mathias W. R., Andres De Roux, Andreas Roth, Karl-Heinz Neumann, Harald Mauch, and Hartmut Lode. 2004. “Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: A Prospective, Randomized Study.” Antimicrobial Agents and Chemotherapy 48:780-82.
25. Rasmussen, Nicolas. 1993. “Facts, Artifacts, and Mesosomes: Practicing Epistemology with the Electron Microscope.” Studies in History and Philosophy of Science A 24:227-65.
26. Rustomjee, R., et al. 2008. “A Phase II Study of the Sterilising Activities of Ofloxacin, Gatifloxacin and Moxifloxacin in Pulmonary Tuberculosis.” International Journal of Tuberculosis and Lung Disease 12:128-38.
27. Shandil, Radha K., Ramesh Jayaram, Parvinder Kaur, Sheshagiri Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, Vrinda Nandi, Sowmya Bharath, and V. Balasubramanian. 2007. “Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium Tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy.” Antimicrobial Agents and Chemotherapy 51:576-82.
28. Soler, Léna, Emiliano Trizio, Thomas Nickles, and William Wimsatt, eds. 2012. Characterizing the Robustness of Science: After the Practice Turn in Philosophy of Science. Dordrecht: Springer.
29. Staley, Kent W. 2004. “Robust Evidence and Secure Evidence Claims.” Philosophy of Science 71:467-88.
30. Stass, H., A. Dalhoff, D. Kubitza, and U. Schühly. 1998. “Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects.” Antimicrobial Agents and Chemotherapy 42:2060-65.
31. Steenwinkel, Jurriaan E. M., Gerjo J. de Knegt, T. Marian, Alex van Belkum, Henri A. Verbrugh, Kristin Kremer, Dick van Soolingen, and Irma A. J. M. Bakker-Woudenberg. 2010. “Time-Kill Kinetics of Anti-tuberculosis Drugs, and Emergence of Resistance, in Relation to Metabolic Activity of Mycobacterium Tuberculosis.” Journal of Antimicrobial Chemotherapy 65:2582-89.
32. Stegenga, Jacob. 2009. “Robustness, Discordance, and Relevance.” Philosophy of Science 76:650-61.
33. Stegenga, Jacob. 2012. “Rerum Concordia Discors: Robustness and Discordant Multimodal Evidence.” In Soler et al. 2012, 207-26.
34. Wang, J. Y., J. T. Wang, T. Tsai, C. Hsu, C. Yu, P. Hsueh, L. Lee, and P. Yang. 2009. “Adding Moxifloxacin Is Associated with a Shorter Time to Culture Conversion in Pulmonary Tuberculosis.” International Journal of Tuberculosis and Lung Disease 14:65-71.
35. Weber, Thomas P., and Nikolaos I. Stilianakis. 2008. “Inactivation of Influenza A Viruses in the Environment and Modes of Transmission: A Critical Review.” Journal of Infection 57:361-73.
36. Weijer, Charles, and Paul B. Miller. 2004. “When Are Research Risks Reasonable in Relation to Anticipated Benefits?” Nature Medicine 10:570-73.
37. Wimsatt, William. 1980. “Reductionist Research Strategies and Their Biases in the Units of Selection Controversy.” In Scientific Discovery: Case Studies, ed. Thomas Nickles, 213-59. Dordrecht: Reidel.
38. Wimsatt, William. 1981. “Robustness, Reliability and Overdetermination.” In Scientific Inquiry and the Social Sciences, ed. M. Brewer, 124-63. San Francisco: Jossey-Bass.
39. Wimsatt, William. 2007. Re-engineering Philosophy for Limited Beings: Piecewise Approximations to Reality. Cambridge, MA: Harvard University Press.
40. Yoshimatsu, Tetsuyuki, Eric Nuermberger, Sandeep Tyagi, Richard Chaisson, William Bishai, and Jacques Grosset. 2002. “Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis.” Antimicrobial Agents and Chemotherapy 46:1875-79.